Search

Displaying results 2081 - 2090 of 6198 in total
  1. Drug

    Givinostat

    go.drugbank.com/drugs/DB12645
    ApprovedInvestigational

    In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.

  2. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

  3. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289].

  4. Drug

    Kappadione

    go.drugbank.com/drugs/DB09332
    Approved

    Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is

  5. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    Dichloroacetic acid, often abbreviated DCA, is an acid analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. … A phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness.

  6. Drug

    Articaine

    go.drugbank.com/drugs/DB09009
    ApprovedInvestigational

    Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.

    Mixtures: ARTICAINA CON ADRENALINA PIERREL, ARTICAINA CON ADRENALINA PIERREL
  7. Drug

    Insulin glulisine

    go.drugbank.com/drugs/DB01309
    Approved

    Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache … Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able

    Products: APIDRA 100 U/ML- SOLUTION FOR INJECTION IN VIAL, APIDRA 100 U/ML SOLOSTAR ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 ADET
  8. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.

  9. Drug

    Dimenhydrinate

    go.drugbank.com/drugs/DB00985
    ApprovedInvestigational

    [L32995] Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. … effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade.

  10. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. … Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth.